Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

CLL State of the Art Update: Ibrutinib Prolongs PFS Compared to CIT, Combinations Achieve uMRD, Venetoclax Obinutuzumab is Highly Effective, & Next Generation BTKi's Are Better Tolerated

324 views
October 18, 2019
Comments 0
Login to view comments. Click here to Login